Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE III, RANDOMIZED, OPEN-LABEL, NON-INFERIORITY COMPARATIVE STUDY BETWEEN SERETIDE® 50/250 ΜG and SALMETEROL/FLUTICASONE SINGLE INHALATION CAPSULE 50/250 ΜG EUROFARMA in PATIENTS with ASTHMA

NCT01202097 is registered in ClinicalTrials.gov with Eurofarma Laboratorios S.A. as lead sponsor.

NCT NCT01202097
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01202097 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE III, RANDOMIZED, OPEN-LABEL, NON-INFERIORITY COMPARATIVE STUDY BETWEEN SERETIDE® 50/250 ΜG and SALMETEROL/FLUTICASONE SINGLE INHALATION CAPSULE 50/250 ΜG EUROFARMA in PATIENTS with ASTHMA
Lead sponsor
Eurofarma Laboratorios S.A.
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2011
Completion date
May 31, 2012
Enrollment
334 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

asthma